Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Farrow Medtech LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, PALLAY, MICHAEL B, who is also the busiest examiner for the company with 1 pending case. The prosecution is confined to 1 distinct art unit, which indicates a very specific and focused technical area for the company's current patenting activity.
With only 1 pending office action, the company's current prosecution workload is light, but the importance of this single case is high. The involvement of 1 distinct examiner, PALLAY, MICHAEL B, means that the prosecution strategy should be tailored specifically to this individual's examination history and preferences. There is no internal data from other pending cases to help predict how this examiner might react compared to others in the same field.
The concentration in 1 distinct art unit suggests that the company is not currently diversifying its intellectual property across multiple technical disciplines. This allows for a streamlined legal strategy focused on the rules and norms of that single art unit. The 1 pending office action represents the totality of the company's current active engagement with the patent office in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.8% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18932569 | Wound-Cleansing Method | PALLAY, MICHAEL B | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18932569 | Wound-Cleansing Method | PALLAY, MICHAEL B | 1617 | §102 | Non-Final OA | — | Pending | Oct 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFarrow Medtech LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael B Pallay has the most, with 1 of Farrow Medtech LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
